Literature DB >> 1860915

Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography.

S W Cheung1, S W Tang, G Remington.   

Abstract

Loxapine, its N-demethylated metabolite amoxapine, and their 7- and 8-hydroxy metabolites were determined simultaneously in plasma by a simple two-step extraction procedure followed by reversed-phase liquid chromatography. Baseline separation was achieved by a 5-microns Spherisorb C6 column. The mobile phase consisted of 5 mM phosphate buffer (with 14 mM orthophosphoric acid)-acetonitrile (with 105 microM nonylamine) (77:23, v/v). Assays of the steady-state plasma samples obtained from seventeen patients on loxapine showed substantial amounts of 8-hydroxy metabolites, lesser amounts of loxapine, amoxapine and 7-hydroxyloxapine and trace amounts of 7-hydroxyamoxapine. As 8-hydroxy metabolites possess only weak dopamine-D2 blocking activity, the final neuroleptic property of loxapine may be affected significantly by metabolic polymorphism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860915     DOI: 10.1016/0378-4347(91)80083-o

Source DB:  PubMed          Journal:  J Chromatogr


  4 in total

1.  Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.

Authors:  Syed Ahmad; Mark A Hughes; Li-An Yeh; John E Scott
Journal:  J Biomol Screen       Date:  2012-04-24

2.  In vitro-in vivo myotoxicity of intramuscular liposomal formulations.

Authors:  S A al-Suwayeh; I R Tebbett; D Wielbo; G A Brazeau
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

3.  Interspecies variability and drug interactions of loxapine metabolism in liver microsomes.

Authors:  Sok Siya Bun; Vireak Voeurng; Hot Bun
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Oct-Dec       Impact factor: 2.441

4.  Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens.

Authors:  Daniel A Spyker; Robert A Riesenberg; James V Cassella
Journal:  J Clin Pharmacol       Date:  2015-05-06       Impact factor: 3.126

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.